Pharmacist perspectives on rising polypharmacy, prescribing cascades, deprescribing, poor coordination, adherence burden, medication review, and safer chronic care.
Audience:
Countries: 6
Survey records: 153
– Hero finding
Quick Read — Key Findings
Explore the clinical pattern, the likely reasons behind it, and what it may mean in practice.
// The backstory
Chronic disease guidelines often improve condition-specific care, but the combined regimen can become difficult to review, coordinate, and follow when several conditions are treated at the same time.
The World Health Organization identifies polypharmacy as a priority area within Medication Without Harm and emphasizes person-centred medication review, multidisciplinary working, and the balance between benefit and avoidable harm.
The survey shows that pharmacists are not mainly worried about the number of medicines in isolation. They are worried about accumulation without reassessment, fragmented prescribing, interaction risk, prescribing cascades, and the burden placed on the patient.
Clinical context: World Health Organization Medication Without Harm and polypharmacy guidance. WHO Medication Without Harm; WHO medication safety in polypharmacy
The survey included pharmacists from the United States, United Kingdom, Canada, Italy, France, and Germany.
Finding 1
A combined 83.5% say polypharmacy has increased significantly or moderately in recent years.
What the pattern suggests: The pattern suggests that chronic-care regimens are growing while the time, ownership, and infrastructure for whole-regimen review may not be growing at the same rate.
Why it matters: This matters because an expanding medicine list increases the chance that duplication, interactions, and outdated indications remain hidden.
Finding 2
During medication reviews, 77.2% say medication burden and interaction risk influence them more than concern about undertreatment.
What the pattern suggests: The pattern does not imply that pharmacists favor stopping treatment. It shows that the combined regimen often creates a safety problem that deserves equal attention to disease control.
Why it matters: This matters because review quality depends on finding the point where additional treatment stops adding net benefit.
Finding 3
More than half, 51.6%, become most concerned when medicines accumulate without reassessment, ahead of adverse effects, adherence decline, or a fixed threshold.
What the pattern suggests: The finding suggests that polypharmacy is defined less by a number and more by the absence of an active review process.
Why it matters: This matters because each additional medicine expands the need to revisit indication, duplication, interaction, and patient burden across the full regimen.
Finding 4
Possible prescribing cascades are encountered frequently by 38.4% and occasionally by 57.6%.
What the pattern suggests: The near-universal exposure suggests that adverse effects being treated as new disease are not rare exceptions. They are a recurring medication-safety risk.
Why it matters: This matters because cascade recognition can prevent additional medicines, reduce harm, and clarify the true source of symptoms.
Finding 5
Lack of coordination among prescribers is the leading barrier to deprescribing at 60.5%.
What the pattern suggests: The pattern suggests that evidence alone is not enough. A medicine may be a reasonable candidate for withdrawal, yet change remains difficult when responsibility is fragmented.
Why it matters: This matters because safe deprescribing requires shared records, clear communication, and a named owner for monitoring.
Finding 6
Complex schedules lead at 44.4%, followed by medication fatigue or burden at 33.9%.
What the pattern suggests: The pattern suggests that poor adherence is often designed into the regimen rather than caused by a lack of motivation.
Why it matters: This matters because simplification can improve safety and consistency without changing the therapeutic intent of care.
Practice implications
The regimen is being judged as one connected system
The strong focus on burden and interactions suggests pharmacists are looking beyond individual indications. A hidden reason is that harm often emerges from how medicines combine, accumulate, and interact across conditions.
Unclear ownership appears to block deprescribing
Coordination outranks patient resistance and time as the main barrier. This points to fragmented responsibility, where several prescribers own individual medicines but no one owns the full regimen.
Simplicity is being treated as a clinical outcome
Quality of life and regimen simplicity lead the difficult trade-off in complex patients. The pattern suggests adherence problems may arise from regimen design rather than patient motivation alone.
The survey shows that pharmacists recognize polypharmacy as a system problem before it becomes an isolated medicine problem. Accumulation, fragmented ownership, prescribing cascades, and complex schedules are all consequences of care delivered in separate pieces.
The clearest opportunity is therefore not simply to count medicines. It is to create a shared review process that connects indications, patient goals, adverse effects, adherence, and responsibility across prescribers.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
You have read the summary
Explore the complete findings in the full report, or join MDForLives to contribute your perspectives to future healthcare research.
//People Also Ask
Direct, current answers to common questions around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
